Pfizer Inc. (PFE) — closed signal from December 30, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 30, 2026 — +11.1% at the close.
Predicted vs. what happened
What happened
Reached its target in 38 days.
The thesis — published December 30, 2025
Pfizer looks like a stock that's fallen more than investors expected and could bounce back short term, helped by its dividend. Short-term momentum readings are negative and recent coverage points to weak three-year returns, so sentiment is fragile. Upcoming Phase 3 PADCEV and Keytruda data could quickly lift expectations. Only consider buying after signs the price has stabilized and keep modest upside goals.
Primary drivers
- Dividend yield may attract cautious investors if rates ease
- Positive Phase 3 PADCEV or Keytruda results could raise expectations fast
- Severely oversold condition could spark a 0-3 month bounce
- Long-term underperformance raises risk of being a value trap
How it played out
PFE: target reached in 38 days
Lyra published PFE at 24.99 on 2025-12-30 with a short-term thesis for 9% expected growth. The thesis pointed to dividend yield support, possible Phase 3 PADCEV or Keytruda data, an oversold setup that could bounce over 0-3 months, and the risk that long-term underperformance was a value trap.
Inside the window, the stock reached the 27.24 target. It peaked at 27.94 on 2026-02-11, with an 11.8% peak gain, and reached the target in 38 days. It ended the window at 27.77 on 2026-03-30. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.